Page 2050 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 120 Transfusion-Transmitted Diseases 1820.e1

REFERENCES 22. Urwin PJM, Mackenzie JM, Llewelyn CA, et al: Creutzfeldt–Jakob
disease and blood transfusion: updated results of the UK Transfu-
1. Busch MP: Cooley Award Lecture. Transfusion-transmitted viral infec- sion Medicine Epidemiology Review Study. Vox Sang 110:310–316,
tions: building bridges to transfusion medicine to reduce risks and 2016.
understand epidemiology and pathogenesis. Transfusion 46:1624, 2006. 23. Snyder EL, Stramer SL, Benjamin RJ: The safety of the blood supply –
2. Custer B, Kessler D, Vahidnia F, et al: For the NHLBI Retrovirus time to raise the bar. N Engl J Med 372:1882–1885, 2015.
Epidemiology Donor Study-II (REDS-II) Risk factors for retrovirus 24. Kleinman Steven, Cameron C, Custer B, et al: Modeling the risk of
and hepatitis virus infections in accepted blood donors. Transfusion an emerging pathogen entering the Canadian blood supply. Transfusion
55:1098–1107, 2014. 50:2592, 2010.
3. Zou S, Stramer SL, Notari EP, et al: Current incidence and residual 25. Aubuchon JP, Prowse CV, editors: Pathogen inactivation: the penultimate
risk of hepatitis B infection among blood donors in the United States. paradigm shift, Bethesda Md, 2010, AABB Press.
Transfusion 49:1609–1620, 2009. 26. Seghatchian J, Hervig T, Putter JS: Effect of pathogen inactivation on
4. Stramer SL, Wend U, Candotti D, et al: Nucleic acid testing to the storage lesion in red cells and platelet concentrates. Transfus Apher
detect HBV infection in blood donors. N Engl J Med 364:236–247, Sci 45:75, 2011.
2011. 27. Bennett JL, Blajchman MA, Delage G, et al: Proceedings of a consensus
5. Taira R, Satake M, Momose S, et al: Residual risk of transfusion- conference: risk-based decision making for blood safety. Transfus Med
transmitted hepatitis B virus (HBV) infection caused by blood Rev 25:267, 2011.
components derived from donors with occult HBV infection in Japan. 28. Jackson BR, Busch MP, Stramer SL, et al: The cost-effectiveness of NAT
Transfusion 1393–1404, 2013. for HIV, HCV, and HBV in whole-blood donations. Transfusion 43:721,
6. FDA Final Rule: Docket No FDA-2006N-0040. Fed Regist 2003.
80(99):29842–29906, 2015. 29. Murphy EL, Glynn SA, Fridey J, et al: Increased prevalence of infectious
7. Stramer SL, Notari EP, Krysztof DE, et al: Hepatitis B virus testing by diseases and other adverse outcomes in human T lymphotropic virus
minipool nucleic acid testing: does it improve blood safety? Transfusion types I- and II-infected blood donors. Retrovirus Epidemiology Donor
53:2449–2458, 2013. Study (REDS) Study Group. J Infect Dis 176:1468, 1997.
8. Kleinman SH, Lelie N, Busch MP: Infectivity of human immuno- 30. Vamvakas EC: Is white blood cell reduction equivalent to antibody
deficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of screening in preventing transmission of cytomegalovirus by transfusion?
transmission by transfusion. Transfusion 49:2454–2489, 2009. A review of the literature and meta-analysis. Transfus Med Rev 19:181,
9. Orton SL, Stramer SL, Dodd RY, et al: Risk factors for HCV infec- 2005.
tion among blood donors confirmed to be positive for the presence of 31. Kleinman Steven H, Glynn SA, Lee TH, et al: A linked donor-recipient
HCV RNA and not reactive for the presence of anti-HCV. Transfusion study to evaluate parvovirus B19 transmission by blood component
44:275–281, 2004. transfusion. Blood 114:3677, 2009.
10. Stramer SL, Dodd RY, Brodsky JP: The value of screening signal-to- 32. Satake M, Hoshi Y, Taira R, et al: Symptomatic parvovirus B19 infection
cutoff ratios for hepatitis C virus antibody confirmation. Transfusion caused by blood component transfusion. Transfusion 51:1887–1895,
53:1497–1500, 2013. 2011.
11. Zou S, Dorsey KA, Notari EP, et al: Prevalence, incidence, and residual 33. Dodd RY: B19: benign or not? Transfusion 51:1878–1879, 2011.
risk of human immunodeficiency virus and hepatitis C virus infections 34. Norja P, Hedman L, Kantola K, et al: Occurrence of human boca-
among United States blood donors since the introduction of nucleic acid viruses and parvovirus 4 in solid tissues. J Med Virol 84:1267–1273,
testing. Transfusion 50:1495–1504, 2010. 2012.
12. Laperche S, Nübling CM, Stramer SL, et al: Sensitivity of hepatitis C 35. Biggerstaff BJ, Petersen LR: Estimated risk of West Nile virus transmis-
virus core antigen and antibody combination assays in a global panel of sion through blood transfusion during an epidemic in Queens, New York
window period samples. Transfusion 55:2489–2498, 2015. City. Transfusion 42:1019, 2002.
13. Petrik J, Lozano M, Seed CR, et al: Hepatitis E. Vox Sang 110:93–103, 36. Pealer LN, Marfin AA, Petersen LR, et al for the West Nile Virus
2016. Transmission Investigation Team: Transmission of West Nile virus
14. Hewitt PE, Ijaz S, Brailsford SR, et al: Hepatitis E virus in blood through blood transfusion in the United States in 2002. N Engl J Med
components: a prevalence and transmission study in southeast England. 349:1236–1245, 2003.
Lancet 384:1766–1773, 2014. 37. Dodd RY: Emerging infections, transfusion safety, and epidemiology. N
15. Stramer SL, Moritz ED, Foster GA, et al: Hepatitis E virus: seropreva- Engl J Med 349:1205–1206, 2003.
lence and frequency of viral RNA detection among U.S. blood donors. 38. Petersen LR, Epstein JS: Problem solved? West Nile virus and transfusion
Transfusion 56:481–488, 2016. safety. N Engl J Med 353:516–517, 2005.
16. Xiang J, Wunschmann S, Diekema DJ, et al: Effect of coinfection with 39. Dodd RY, Foster GA, Stramer SL: Keeping blood transfusion safe from
GB virus C on survival among patients with HIV infection. N Engl J West Nile virus: American Red Cross experience, 2003-2012. Transfus
Med 345:704, 2001. Med Rev 29:153–161, 2015.
17. Berg MG, Lee D, Coller K, et al: Discovery of a novel human pegivirus 40. Zou S, Foster GA, Dodd RY, et al: West Nile fever characteristics among
in blood associated with hepatitis C virus co-infection. PLoS Pathog viremic persons identified through blood donor screening. J Infect Dis
11(e1005325):2015. 202:1354, 2010.
18. Brennan CA, Yamaguchi J, Devare SG, et al: Expanded evaluation of 41. Stramer SL, Fang CT, Foster GA, et al: West Nile virus among blood
blood donors in the United States for human immunodeficiency virus donors in the United States, 2003 and 2004. N Engl J Med 353:451–459,
type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 2005.
through 2007. Transfusion 50:2707, 2010. 42. Tomashek KM, Margolis HS: Dengue: a potential transfusion-transmitted
19. Centers for Disease Control and Prevention: HIV transmission through disease. Transfusion 51:1654, 2011.
transfusion—Missouri and Colorado, 2008. MMWR 59(1335): 43. Stramer SL, Linnen JM, Carrick JM, et al: Dengue viremia in blood
2010. donors identified by RNA and detection of dengue transfusion trans-
20. Centers for Disease Control and Prevention and Association of Public mission during the 2007 dengue outbreak in Puerto Rico. Transfusion
Health Laboratories: Laboratory Testing for the Diagnosis of HIV Infec- 52:1657–1666, 2012.
tion: Updated Recommendations. Available at http://dx.doi.org/10.15620/ 44. Matos D, Tomashek KM, Perez-Padilla J, et al: Probable and possible
cdc.23447. Published June 27, 2014. Accessed 31.01.16. transfusion-transmitted dengue associated with NS1-antigen negative
21. Seed CR, Kiely P, Law M, et al: No evidence of a significantly increased but RNA-confirmed-positive red blood cells. Transfusion 56:215–222,
risk of transfusion-transmitted human immunodeficiency virus infection 2015.
in Australia subsequent to implementing a 12-month deferral for men 45. Sabino E, Loureiro P, Lopes M, et al: Transfusion-transmission of
who have had sex with men. Transfusion 50:2722, 2010. dengue virus and associated clinical symptomatology during the 2012